Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 3/20 | 0.44 |
| ▸ | USP7 | Q93009 | 2/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.38 |
| ▸ | ESR1 | P03372 | 2/20 | 0.38 |
| ▸ | DHFR | P00374 | 1/20 | 0.38 |
| ▸ | HEXA | P06865 | 1/20 | 0.38 |
| ▸ | HEXB | P07686 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | BRD2 | P25440 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2492230 | 0.86 | GCGR (0.38) | GCGRUSP7DHFRHEXAHEXB | |
| SCHEMBL28769956 | 0.84 | USP7 (0.47) | GCGRUSP7ESR2ESR1DHFR | |
| SCHEMBL2492131 | 0.83 | GCGR (0.45) | GCGRDHFR | |
| SCHEMBL9579775 | 0.78 | GCGR (0.41) | GCGRUSP7ESR2ESR1DHFR | |
| SCHEMBL7108430 | 0.78 | GCGR (0.41) | GCGRUSP7ESR2ESR1DHFR | |
| SCHEMBL30234292 | 0.78 | ESR2 (0.53) | GCGRUSP7ESR2ESR1DHFR | |
| SCHEMBL2201812 | 0.78 | ESR2 (0.53) | GCGRUSP7ESR2ESR1DHFR | |
| SCHEMBL28518728 | 0.77 | GCGR (0.38) | GCGRUSP7ESR2ESR1DHFR | |
| Formaldehyde SCHEMBL29141443 | 0.77 | ESR2 (0.49) | GCGRUSP7ESR2ESR1KDM4E | |
| SCHEMBL4870784 | 0.76 | LMNA (0.39) | ESR2PTGS1PTGS2BRD4BRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2380567-B1 | MELANIN PRODUCTION INHIBITOR | POLA CHEM IND INC (JP) | 2019-01-16 | — | — | EP | disclosed |
| EP-3009123-A1 | MELANIN PRODUCTION INHIBITOR | Pola Chemical Industries Inc. (JP) | 2016-04-20 | — | — | EP | disclosed |
| US-20150328107-A1 | MELANIN PRODUCTION INHIBITOR | POLA CHEMICAL INDUSTRIES INC. (JP) | 2015-11-19 | — | — | US | disclosed |
| EP-2845587-A2 | Melanin production inhibitor | Pola Chemical Industries Inc. (JP) | 2015-03-11 | — | — | EP | disclosed |
| US-20140363389-A1 | MELANIN PRODUCTION INHIBITOR | POLA CHEMICAL INDUSTRIES INC. (JP) | 2014-12-11 | — | — | US | disclosed |
| US-8846012-B2 | Melanin production inhibitor | POLA CHEMICAL INDUSTRIES INC. (JP) | 2014-09-30 | — | — | US | disclosed |
| EP-2380567-A1 | MELANIN PRODUCTION INHIBITOR | Pola Chemical Industries Inc. (JP) | 2011-10-26 | — | — | EP | disclosed |
| US-20110243865-A1 | MELANIN PRODUCTION INHIBITOR | POLA CHEMICAL INDUSTRIES INC. (JP) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110243865-A1 | MELANIN PRODUCTION INHIBITOR | TYR, F12, TH | GCGR 885/4885USP7 2522/4885ESR2 3511/4885 |
| US-20150328107-A1 | MELANIN PRODUCTION INHIBITOR | TYR, MC1R, F12 | GCGR 808/4885USP7 2499/4885ESR2 3465/4885 |
| US-20140363389-A1 | MELANIN PRODUCTION INHIBITOR | TYR, F12, MC1R | GCGR 839/4885USP7 2529/4885ESR2 3449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.